No Data
CSPC PHARMA (01093): CSPC's innovative Q1 parent net loss of 26.9016 million yuan.
CSPC PHARMA (01093) announced that its subsidiary CSPC Innovative Pharmaceuticals Co., Ltd. (CSPC Innovative) has ...
CSPC PHARMA: UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2025
CSPC Pharmaceutical Gets FDA Nod for Cancer Cachexia Drug Trial
Hong Kong stock movement | CSPC PHARMA (01093) rises more than 3% again, approval received for clinical trial of Ploglitazone Metformin Extended-Release Tablets.
CSPC PHARMA (01093) rose over 3% again, as of the time of writing, it increased by 3.31%, priced at 6.25 HKD, with a transaction volume of 0.654 billion HKD.
CSPC PHARMA (01093.HK): JMT203 (anti-GFRAL monoclonal antibody) has been approved for clinical trials in the USA.
On April 22, Gelonghui reported that CSPC PHARMA (01093.HK) announced that its subsidiary Shanghai Jinman Te Biotechnology Co., Ltd. has independently developed the antibody drug JMT203, which has been approved by the USA Food and Drug Administration (FDA) to conduct clinical research in the USA. Previously, the product was approved by the China National Medical Products Administration in June 2023 and is currently undergoing clinical trials in China. This product is an anti-GDNF family receptor protein (GFRAL) recombinant humanized monoclonal antibody independently developed by the group, which can effectively antagonize the GDF15-GFRAL/RET signal.
Express News | CSPC Pharmaceutical - Prusogliptin and Metformin Extended-Release Tablets Obtains Clinical Trial Approval From Nmpa
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}